Overview

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

Status:
COMPLETED

Trial end date:
2024-09-27

Target enrollment:

Participant gender:

Summary

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) following multiple rising doses of BI 3000202 and to investigate the effect of BI 3000202 on the metabolism of midazolam.

Phase:

PHASE1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Midazolam